These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 35010576)
21. The role of medicine donations in the global programme for the elimination of lymphatic filariasis. Williams T; Taylor R; Iwamoto M; Hida T; Gusovsky F Int Health; 2020 Dec; 13(Suppl 1):S39-S43. PubMed ID: 33349878 [TBL] [Abstract][Full Text] [Related]
22. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission. Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758 [TBL] [Abstract][Full Text] [Related]
23. Integrated morbidity management for lymphatic filariasis and podoconiosis, Ethiopia. Deribe K; Kebede B; Tamiru M; Mengistu B; Kebede F; Martindale S; Sime H; Mulugeta A; Kebede B; Sileshi M; Mengiste A; McPherson S; Fentaye A Bull World Health Organ; 2017 Sep; 95(9):652-656. PubMed ID: 28867846 [TBL] [Abstract][Full Text] [Related]
24. Caring for patients in the global programme to eliminate lymphatic filariasis. Mackenzie CD; Mante S Int Health; 2020 Dec; 13(Suppl 1):S48-S54. PubMed ID: 33349884 [TBL] [Abstract][Full Text] [Related]
25. Burden of lymphatic filariasis morbidity in an area of low endemicity in Brazil. Netto MJ; Bonfim C; Brandão E; Aguiar-Santos AM; Medeiros Z Acta Trop; 2016 Nov; 163():54-60. PubMed ID: 27427218 [TBL] [Abstract][Full Text] [Related]
26. Imported bancroftian filariasis: diethylcarbamazine response and benzimidazole susceptibility of Wuchereria bancrofti in dynamic cross-border migrant population targeted by the National Program to Eliminate Lymphatic Filariasis in South Thailand. Bhumiratana A; Pechgit P; Koyadun S; Siriaut C; Yongyuth P Acta Trop; 2010 Feb; 113(2):121-8. PubMed ID: 19835831 [TBL] [Abstract][Full Text] [Related]
27. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007). Hooper PJ; Bradley MH; Biswas G; Ottesen EA Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394 [TBL] [Abstract][Full Text] [Related]
28. Mass drug administration to eliminate lymphatic filariasis in India. Ramaiah KD; Das PK Trends Parasitol; 2004 Nov; 20(11):499-502. PubMed ID: 15471698 [TBL] [Abstract][Full Text] [Related]
29. Current status and future prospects of the Global Lymphatic Filariasis Programme. Molyneux DH; Taylor MJ Curr Opin Infect Dis; 2001 Apr; 14(2):155-9. PubMed ID: 11979126 [TBL] [Abstract][Full Text] [Related]
30. Assessment of transmission in areas of uncertain endemicity for lymphatic filariasis in Brazil. Xavier A; Oliveira H; Aguiar-Santos A; Barbosa Júnior W; da Silva E; Braga C; Bonfim C; Medeiros Z PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007836. PubMed ID: 31765388 [TBL] [Abstract][Full Text] [Related]
31. Assessing numbers and faces: a prerequisite for improving access to lymphatic filariasis morbidity care. Becker SL; Fürst T; Addiss DG; Utzinger J Trans R Soc Trop Med Hyg; 2015 Jun; 109(6):357-9. PubMed ID: 25778735 [TBL] [Abstract][Full Text] [Related]
32. Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects. Chandrasena N; Premaratna R; Gunaratna IE; de Silva NR PLoS Negl Trop Dis; 2018 May; 12(5):e0006472. PubMed ID: 29746479 [TBL] [Abstract][Full Text] [Related]
33. The story of Lymphatic Filariasis elimination as a public health problem from Yemen. Al-Kubati AS; Al-Samie AR; Al-Kubati S; Ramzy RMR Acta Trop; 2020 Dec; 212():105676. PubMed ID: 32828916 [TBL] [Abstract][Full Text] [Related]
34. Evaluating the availability and quality of services for lymphatic filariasis morbidity in Ghana. Edmiston M; Atinbire S; Mensah EO; Mensah E; Alomatu B; Asemanyi Mensah K; Palmer S PLoS Negl Trop Dis; 2023 Jun; 17(6):e0010805. PubMed ID: 37307289 [TBL] [Abstract][Full Text] [Related]
35. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa. Silumbwe A; Zulu JM; Halwindi H; Jacobs C; Zgambo J; Dambe R; Chola M; Chongwe G; Michelo C BMC Public Health; 2017 May; 17(1):484. PubMed ID: 28532397 [TBL] [Abstract][Full Text] [Related]
36. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors. Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788 [TBL] [Abstract][Full Text] [Related]
37. Lymphatic filariasis morbidity mapping: a comprehensive examination of lymphoedema burden in Chikwawa district, Malawi. Smith EL; Mkwanda SZ; Martindale S; Kelly-Hope LA; Stanton MC Trans R Soc Trop Med Hyg; 2014 Dec; 108(12):751-8. PubMed ID: 25282001 [TBL] [Abstract][Full Text] [Related]
38. Lymphatic filariasis in Papua New Guinea: prospects for elimination. Bockarie MJ; Kazura JW Med Microbiol Immunol; 2003 Feb; 192(1):9-14. PubMed ID: 12592558 [TBL] [Abstract][Full Text] [Related]
39. Managing morbidity and preventing disability in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement. Wkly Epidemiol Rec; 2011 Dec; 86(51-52):581-5. PubMed ID: 22191103 [No Abstract] [Full Text] [Related]
40. Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination. Alexander ND Trans R Soc Trop Med Hyg; 2015 Mar; 109(3):173-4. PubMed ID: 25575555 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]